A negative correlation was observed between the expression of SLC35A2 and the TIDE score in 20 tumors, including BLCA, LUAD, and LUSC, suggesting the expression of SLC35A2 is correlated with ICB response and may serve as a marker for ICB treatment (Figure 9E). Here, SLC35A2 is linked to bladder transitional cell carcinoma.